Changes in Beneficial Ownership · 4
Canton Strategic Holdings, Inc.
CNTNNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-23
- Issuer
- Canton Strategic Holdings, Inc.
- Issuer CIK
- 0001861657
- Trading symbol
- CNTN
Reporting owner 1
- Name
- Sommers Jill E.
- Reporting owner CIK
- 0001737622
- Relationship
- Director
- Address
- CANTON STRATEGIC HOLDINGS, INC, 1460 BROADWAY, NEW YORK, NY, 10036
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 1.86 | 2026-10-23 | A · Form 4 | 53,763 | A | [F2] | [F1] | 2036-10-23 | Common Stock | 53,763 | 53,763 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Grant of option to purchase Common Stock under the Issuer's Amended and Restated 2023 Omnibus Equity Incentive Plan. Of the shares subject to the option, (i) 26,881 shares were vested as of October 23, 2026, (ii) 13,441 shares shall vest on November 1, 2026, and (iii) the remaining 13,441 shares shall vest on February 1, 2027, in each case subject to the Reporting Person's continuous service as a member of the Issuer's board of directors immediately prior to the applicable vesting date.↩ 1
- F2
- This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy as an annual director equity grant.↩ 1
Signature 1
- Signed
- /s/ Jill Sommers
- Date
- 2026-10-27
Company context
Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick™Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: www.tharimmune.com.